Application of casein kinase 1 inhibitors in the treatment of vascular diseases

By targeting casein kinase 1 (CK1) activity development inhibitors, the problem that microvascular system treatment methods cannot effectively improve organ function is solved, significantly reduce peripheral resistance and blood pressure, improve the symptoms of cardiovascular disease, and provide a safe and effective Treatment plan.

CN113301900BActive Publication Date: 2024-11-29QANATPHARMA AG
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN201980068381.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-09-09
Publication Date
2024-11-29
Estimated Expiration
2039-09-09

AI Technical Summary

Technical Problem

Existing microvascular system treatment methods cannot effectively improve organ function and are difficult to achieve effective doses without causing major side effects, especially in hypertension and cardiovascular diseases, where myogenic response deterioration leads to peripheral resistance and blood pressure regulation difficulty.

Method used

By selectively targeting the regulation of casein kinase 1 (CK1) activity, CK1 inhibitors are developed to reduce myogenic response, thereby improving the function and systemic hemodynamics of the peripheral vascular system, especially in heart failure and arachnoid membranes In diseases such as subcavity bleeding and hypertension.

Benefits of technology

CK1 inhibitors can reduce total peripheral resistance and blood pressure while retaining normal physiological regulatory mechanisms, improve organ blood flow and function, reduce cardiac afterload, reduce systemic blood pressure, and do not affect agonist-induced vasoconstriction. Under the following, the symptoms of various cardiovascular diseases are significantly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113301900B_ABST
    Figure CN113301900B_ABST
Patent Text Reader

Abstract

The present invention relates to the use of a tyrosine kinase 1 inhibitor in treating vascular diseases, preferably peripheral vascular diseases, and to corresponding treatment methods.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to the use of a casein kinase 1 inhibitor in treating vascular diseases, preferably peripheral vascular diseases, and also relates to corresponding treatment methods.

[0002] Despite significant investments in basic and clinical cardiovascular research, cardiovascular disease remains the most devastating and challenging health problem worldwide: cardiovascular disease causes more than 17,500,000 deaths each year (47% of all non-communicable disease deaths), and the global cost of managing cardiovascular disease will rise to $1.04 trillion by 2030, transforming this health problem into a serious threat to the global economy.

[0003] High blood pressure is the No. 1 risk factor for all cardiovascular diseases: it increases the risk of heart attack, heart failure (HF), stroke and kidney failure. Up to one in three people have high blood pressure. However, because high blood pressure has few signs or symptoms, most cases remain undiagnosed. We do not understand why people develop high blood pressure: only 10% of high blood pressure cases can be explained. Understanding high blood pressure is key to preventing and treating cardiovascular disease.

[0004] Microvascular research studies the structure and function of the smallest blood vessels (precapillary arterioles and postcapillary venules) in health and disease. Resistance arteries are "hot spots" within the cardiovascular system that regulate mean arterial blood pressure (MAP) and tissue perfusion and are responsible for generating the largest portion of total peripheral resistance (TPR). Therefore, alterations in their structure and function (e.g. due to disease or aging) immediately affect tissue perfusion and MAP. Resistance arteries represent an untapped opportunity to improve cardiovascular health. Understanding the structural and molecular basis of microvascular function in health and disease will unlock a host of new therapeutic strategies.

[0005] Current treatments targeting the microvasculature are substandard because they fail to improve organ function and are difficult to titrate to effective doses without causing significant side effects. For example, increased myogenic tone in HF increases TPR and causes an “afterload mismatch” that has deleterious long-term effects on ventricular morphology and cardiac function. In fact, even short-term increases in afterload can cause significant infarct enlargement. Therefore, several approaches to reduce cardiac afterload have been evaluated, but with only limited success. Although reducing cardiac afterload may provide cardiac benefits, vasodilators such as nitric oxide carry the risk of abolishing myogenic responsiveness and dangerously lowering TPR and blood pressure.

[0006] Myogenic responsiveness and its impact on systemic hemodynamics: In 1902, Sir William Bayliss discovered that increased transmural pressure causes resistance arteries to "squirm like a worm" (i.e., constrict)1 This observation was later called myogenic responsiveness 2-5 , describes this dynamic regulation of vessel diameter in response to changing perfusion pressure. As the etymology of its name implies (myo = muscle, genic = generated), myogenic responsiveness originates in the smooth muscle layer of the vessel wall. 6-8 ; Anatomically, myogenic responsiveness is a property of the small precapillary arteries and arterioles (ie, small diameter "resistance arteries" are functionally distinct from large diameter conduit arteries).

[0007] At the system level, Ohm's law states that resistance artery myogenic responsiveness will affect TPR and MAP. 9,10 This positions resistance arteries as “functional hotspots” in several disease processes characterized by alterations in tissue perfusion and / or systemic hemodynamics, including cardiomyopathies 11 HF 12,13 ,diabetes 14,15 and high blood pressure 16 Skeletal muscle resistance arteries in vivo significantly modulate TPR, as this vascular bed forms the largest circulatory network in the human body. 17 .

[0008] TNF reverse signaling as a regulator of myogenic responsiveness: seminal studies in our study of skeletal muscle resistance arteries 18 Here, we demonstrate that tumor necrosis factor (TNF), specifically membrane-bound TNF (mTNF), is a constitutive mechanosensor that drives myogenic responsiveness in skeletal muscle resistance arteries under nonpathological conditions. Accordingly, acute deletion of the TNF gene in smooth muscle cells or depletion of TNF with etanercept attenuates the myogenic responsiveness of skeletal muscle resistance arteries, thereby reducing systemic blood pressure. Remarkably, the inhibitory effects of etanercept on skeletal muscle arterial myogenic responsiveness are conserved across five different species, including humans. Mechanistically, mTNF converts mechanical loads imposed on vascular smooth muscle cells into an outside-in signal (i.e., a ‘reverse signal’ generated by TNF) that interfaces with established intracellular myogenic signaling components such as ERK 1 / 2 and sphingosine kinase 1. This non-classical mTNF reverse signaling mechanism appears to be unique to skeletal muscle resistance arteries. 18 .

[0009] Casein kinase 1 is a regulator of TNF reverse signaling: The cytoplasmic domain of TNF has no discernible enzymatic function and therefore signals through associated proteins including casein kinase 1 (CK1). Notably, evolutionary pressures have conserved the CK1 phosphorylation site of TNF across multiple species, suggesting that it plays a key role 19In this regard, phosphorylation of TNF acts as an “activity switch” and provides a flexible mechanism to regulate the reverse signaling function of TNF.

[0010] CK1 is a family of seven ubiquitously expressed monomeric serine / threonine protein kinases 20 Although all CK1 isoforms share a highly conserved kinase domain, they differ significantly in their non-catalytic N- and C-terminal domains. 21,22 :These domains play crucial roles in regulating kinase activity, kinase localization and substrate specificity in vivo 21-23 Since CK1 family isoforms exhibit similar substrate specificity in vitro 24 , thus their distinct biological functions in vivo (e.g., chromosome segregation, spindle formation, circadian rhythms, nuclear import, Wnt pathway signaling, and cell survival / apoptosis) arise almost entirely from differences in localization, docking sequences, and interaction partners. 22 .

[0011] All CK1 isoforms are constitutively active and are therefore classified as "second messenger-independent kinases". Canonically, CK1 phosphorylates the "primed" (pre-phosphorylation) consensus sequence S(P)-XXS, where "S(P)" represents the "primed" phosphoserine, "X" represents any amino acid, and "S" represents the target serine for CK1 phosphorylation. 20 Since phosphorylated serine residues are required for efficient substrate recognition, CK1 often phosphorylates substrates together with other kinases. 20 This is consistent with the hierarchical phosphorylation mechanism. 25 .

[0012] The technical problem underlying the present invention is to provide a new approach for improving myogenic responsiveness in the peripheral vascular system.

[0013] According to the present invention, the term "improving myogenic responsiveness in the peripheral vascular system" refers to improving myogenic responsiveness, especially in a disease state or disorder, in particular in a disease state or condition in which myogenic responsiveness is deteriorated, in particular in the case of specific diseases and conditions as described more specifically below. The myogenic responsiveness in the peripheral vascular system of a subject shows a deteriorated myogenic responsiveness in the peripheral vascular system compared to a healthy subject, said myogenic responsiveness being normalized or at least altered in the direction of the normalized value.

[0014] A solution to the above-mentioned technical problem is provided by the embodiments of the present invention as disclosed in the claims, this specification and the accompanying drawings.

[0015] The inventors have discovered an elegant means of reducing TPR by selectively targeting mechanisms that regulate discrete components of myogenic responsiveness. Vascular bed-specific modulation of myogenic responsiveness can improve organ blood flow and function while fully preserving normal physiological regulatory mechanisms.

[0016] According to the present invention, compounds that alter the expression activity of vascular smooth muscle CK1 have an effect on mTNF reverse signaling and myogenic responsiveness, and therefore have an effect on total peripheral resistance, tissue blood flow and systemic blood pressure. Since changes in myogenic responsiveness are a hallmark of many diseases (e.g., heart failure, subarachnoid hemorrhage, diabetes, stroke, sepsis), targeting microvascular CK1 activity / expression has the potential to improve microvascular myogenic responsiveness and systemic hemodynamics in a variety of diseases.

[0017] More specifically, the present invention provides the use of casein kinase 1 (CK1) inhibitors, that is, one or more CK1 inhibitors can be used to prevent and / or treat vascular and / or cardiovascular diseases (CVD), such as coronary artery disease (CAD) (angina and myocardial infarction (commonly known as heart attack)), stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, myocarditis, aortic aneurysm, peripheral arterial disease, thromboembolic disease, venous thrombosis, subarachnoid hemorrhage and hypertension, among which heart failure, subarachnoid hemorrhage and hypertension are particularly preferred.

[0018] According to the present invention, a CK1 inhibitor is a compound that reduces the expression and / or activity of CK1.

[0019] Preferred CK1 inhibitors for use in the present invention are inhibitors that are selective for CK1 isoforms δ (CK1δ, also referred to as "CK1D" in other cases) and / or ε (CK1ε, also referred to as "CK1E" in other cases). In certain embodiments of the present invention, it is preferred when the CK1 inhibitor has a higher inhibitory effect on CK1δ than on CK1ε. Particularly suitable CK1 inhibitors for use in the present invention are the CK1 inhibitors disclosed in WO 2014 / 023271, more preferably CK1 inhibitors D4476, PF670462, IC261 and PF 4800567. Highly preferred CK1 inhibitors for use in the present invention are PF-670462 and PF-4800567, which may also be used in combination. Other useful CK1 inhibitors within the scope of the present invention are the CK1δ selective inhibitors disclosed in Salado et al. (2014 J.Med.Chem.2014, 57, 2755-2772), in particular Figure 1, Table 1 and Figure 2The compounds shown, most preferably compound M3-15. It should also be understood that the present invention also relates to the use of pharmaceutically acceptable salts, solvates, esters, salts of esters and any other adducts or derivatives, which can directly or indirectly provide the Ck1 inhibitor or its metabolite or residue for use in the present invention after administration to a patient in need thereof.

[0020] According to the present invention, CK1 inhibitors inhibit CK1 expression / activity and reduce mTNF reverse signaling in vascular smooth muscle cells of peripheral resistance arteries, particularly in patients suffering from diseases such as vascular and cardiovascular diseases (CVD), such as coronary artery disease (CAD) (angina and myocardial infarction (commonly known as heart disease)), stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, myocarditis, aortic aneurysm, peripheral arterial disease, thromboembolic disease, venous thrombosis, subarachnoid hemorrhage and hypertension, among which heart failure, subarachnoid hemorrhage and hypertension are particularly preferred.

[0021] According to the present invention, CK1 inhibitors reduce smooth muscle Erk1 / 2 phosphorylation and sphingosine-1-phosphate signaling in diseases such as heart failure, especially in patients with diseases such as vascular and cardiovascular diseases (CVD), such as, for example, coronary artery disease (CAD) (angina and myocardial infarction (commonly known as heart disease)), stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, myocarditis, aortic aneurysm, peripheral arterial disease, thromboembolic disease, venous thrombosis, subarachnoid hemorrhage and hypertension, among which heart failure, subarachnoid hemorrhage and hypertension are particularly preferred.

[0022] According to the present invention, CK1 inhibitors inhibit CK1 expression / activity and reduce peripheral myogenic responsiveness, particularly in patients suffering from diseases such as vascular and cardiovascular diseases (CVD), such as, for example, coronary artery disease (CAD) (angina and myocardial infarction (commonly known as heart disease)), stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, myocarditis, aortic aneurysm, peripheral arterial disease, thromboembolic disease, venous thrombosis, subarachnoid hemorrhage and hypertension, among which heart failure, subarachnoid hemorrhage and hypertension are particularly preferred.

[0023] According to the invention, CK1 inhibitors reduce total peripheral resistance, in particular in patients suffering from diseases such as vascular and cardiovascular diseases (CVD), such as, for example, coronary artery disease (CAD) (angina and myocardial infarction (commonly known as heart disease)), stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmias, congenital heart disease, valvular heart disease, myocarditis, aortic aneurysm, peripheral arterial disease, thromboembolic disease, venous thrombosis, subarachnoid hemorrhage and hypertension, of which heart failure, subarachnoid hemorrhage and hypertension are particularly preferred.

[0024] According to the invention, CK1 inhibitors lower systemic blood pressure, in particular in patients suffering from diseases such as vascular and cardiovascular diseases (CVD), such as, for example, coronary artery disease (CAD) (angina and myocardial infarction (commonly known as heart disease)), stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmias, congenital heart disease, valvular heart disease, myocarditis, aortic aneurysm, peripheral arterial disease, thromboembolic disease, venous thrombosis, subarachnoid hemorrhage and hypertension, of which heart failure, subarachnoid hemorrhage and hypertension are particularly preferred.

[0025] According to the invention, CK1 inhibitors increase blood flow in skeletal muscle, mesentery, kidney and coronary circulation, in particular in patients suffering from diseases such as vascular and cardiovascular diseases (CVD), such as, for example, coronary artery disease (CAD) (angina and myocardial infarction (commonly known as heart disease)), stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmias, congenital heart disease, valvular heart disease, myocarditis, aortic aneurysm, peripheral arterial disease, thromboembolic disease, venous thrombosis, subarachnoid hemorrhage and hypertension, of which heart failure, subarachnoid hemorrhage and hypertension are particularly preferred.

[0026] According to the present invention, the effects of CK1 inhibitors are limited to myogenic tension; catecholamine-induced vasoconstriction is not affected in diseases such as heart failure, subarachnoid hemorrhage and hypertension.

[0027] According to the invention, the action of CK1 inhibitors is limited to the peripheral and coronary circulation; cerebrovascular hemodynamics are not affected in the diseases mentioned above, in particular in heart failure, subarachnoid hemorrhage and hypertension.

[0028] The present invention also relates to a CK1 inhibitor for use in the prevention and / or treatment of vascular and / or cardiovascular diseases as described above, preferably a CK1 inhibitor selected from those described in detail above.

[0029] The present invention also relates to a method for preventing and / or treating vascular diseases and / or cardiovascular diseases as described above, which method comprises administering to a patient in need thereof, in particular a mammalian patient, in particular a human patient, an effective amount of at least one CK1 inhibitor, preferably at least one CK1 inhibitor selected from those described in detail above.

[0030] In the present invention, the effect of the CK1δ / ε-selective inhibition platform was shown, leading to the conclusion that maximal CK1 inhibition only partially attenuated myogenic vasoconstriction. In response to this comment, we performed another experiment to confirm the efficacy of CK1 inhibition in the setting of heart failure (HF), as an exemplary disease for treatment according to the present invention using CK1 inhibitors.

[0031] According to the present invention, one or more CK1 inhibitors can be used in their / their free form. In other embodiments, the CK1 inhibitor (i.e., at least one CK1 inhibitor) used in the present invention is present in a pharmaceutical composition, which comprises the at least one CK1 inhibitor, usually in combination with at least one pharmaceutically acceptable excipient, diluent, carrier and / or carrier.

[0032] The effective amount of a CK1 inhibitor employed in the methods and uses of the present invention, i.e., the specific effective dosage level for any particular patient or organism will depend on a variety of factors, including the disease being treated and the severity of the disease; the activity of the specific compound employed; the specific composition employed; the age, weight, general health, sex and diet of the patient; the time of administration, route of administration and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or concomitantly with the specific compound employed, and similar factors well known in the medical arts.

[0033] In the context of the present invention, with particular reference to the preferred compounds referred to herein, more particularly PF-4800567 and PF-670462, the preferred dosage is from about 0.1 to about 300 mg / kg body weight (hereinafter referred to as "mg / kg"), preferably from about 10 to about 100 mg / kg, more preferably from about 20 to about 70 mg / kg, particularly preferably from about 25 to about 45 mg / kg, for example 30 mg / kg. The dosage may be administered once or more, for example twice or three times a day. Preferably, it is administered once or twice a day. The preferred administration of one or more CK1 inhibitors is once a day.

[0034] As is well known, many cardiovascular events typically occur during the resting state, i.e., at night when human patients are involved. Therefore, at least one CK1 inhibitor is preferably administered according to a regimen that provides the maximum pharmacological effect of at least one CK1 during the resting state of the subject being treated, more preferably at or around mid-rest, wherein "mid-rest" is preferably about -2 to about +2 hours in mid-rest, more preferably about -1 to about +1 hours in mid-rest, and even more preferably about -0.5 to about +0.5 hours in mid-rest. It is obvious to those skilled in the art that the regimen that provides the maximum pharmacological effect of at least one CK1 inhibitor depends on the selected CK1 inhibitor. For example, a CK1 inhibitor that exhibits relatively rapid degradation of the active compound can be administered once a day at a suitable time before the resting period (i.e., before bedtime for human patients), such as 3, 4, 5, or 6 hours before the patient's resting period. In an alternative embodiment in which the selected CK1 inhibitor is a compound that exhibits slow degradation, the CK1 inhibitor can be administered by a controlled release composition to ensure that the inhibitor has the maximum effect during the resting period (preferably at or about mid-rest), typically with the maximum bioavailable concentration in the treated patient. Appropriate pharmaceutical compositions and / or dosages and administration regimens employing specific CK1 inhibitors as outlined in more detail herein for providing the above-mentioned maximal effects during the resting period are known to those skilled in the art.

[0035] The route of administration of the CK1 inhibitor is not particularly critical and the route chosen depends on the individual CK1 inhibitor compound and the subject being treated.Preferably, the CK1 inhibitor is administered systemically, such as orally or intravenously, with oral administration being particularly preferred.

[0036] As used herein, the term "patient" refers to an animal, preferably a mammal, most preferably a human.

[0037] At least one CK1 inhibitor used according to the present invention, preferably a CK1 inhibitor in the presence of the pharmaceutical composition outlined above, can be administered using any amount and any route of administration effective for treating cerebrovascular disease. According to the present invention, it is understood that the term "treatment" means that the severity of the disease at least does not progress compared to the untreated disease, preferably the severity of the disease does not progress, more preferably the severity of the condition is reduced, even more preferably the severity of the condition is substantially reduced, and ideally the condition is cured to a substantial extent. Preferably, the severity of the condition of the present invention is reduced by at least 30%, more preferably by at least 50%, in particular by at least 70%, even more preferably by at least 90%, wherein complete cure of the condition is the most preferred outcome of the treatment of the present invention.

[0038] The attached figure shows:

[0039] Figure 1: (A) Prior to treatment, myogenic tone was increased in cremaster arteries isolated from mice with HF (n=6) relative to arteries isolated from sham controls (n=8). (B) Following in vitro treatment with 550 nM PF670462 (30 min), myogenic tone was attenuated to the same level in both groups. Thus, the HF-mediated increase in myogenic tone was abolished (i.e., the curves overlapped after treatment) and the new tone level was only modestly reduced compared to sham.

[0040] Figure 2 : Showing that the cytoplasmic portion of mTNF regulates reverse signaling.

[0041] Figure 3 : Show that casein kinase 1 regulates mTNF-mediated myogenic responsiveness.

[0042] Figure 4 : Showing that casein kinase 1δ regulates myogenic responsiveness.

[0043] Figure 5 : Show that CK1D regulates circadian oscillations in myogenic responsiveness.

[0044] Figure 6 : Show that CK1D inhibition improves microvascular dysfunction and cardiac function in HF.

[0045] The present invention is further illustrated by the following non-limiting examples. Example

[0046] Example 1: CK1 inhibition reduces myogenic responsiveness in vitro and in vivo

[0047] Referring to Figure 1, microvascular smooth muscle cells were cultured from mouse mesenteric arteries and ERK1 / 2 phosphorylation was assessed by standard Western blotting. Rat cremaster skeletal muscle resistance arteries were assessed by pressure electromyography. mTNF reverse signaling was induced by the intrinsically active TNF type I receptor construct sTNFR1-Fc.

[0048] In microvascular smooth muscle cells, sTNFR1-Fc increased ERK1 / 2 phosphorylation. Both the pan CK1 inhibitor CKI-7 and the specific CKIδ inhibitor PF-670462 abolished sTNFR1-Fc-induced ERK1 / 2 phosphorylation. These findings were confirmed in cremaster skeletal muscle resistance arteries. In vitro application of CKI-7 abolished sTNFR1-Fc-induced mTNF reverse signaling and reduced myogenic responsiveness. CK1 inhibition did not affect TNF - / -PF-670462 also reduced myogenic responsiveness in vitro, and when applied in vivo, PF-67062 reduced myogenic responsiveness in isolated cremaster arteries. Importantly, none of the above treatments affected agonist-induced vasoconstriction.

[0049] Example 2: The cytoplasmic portion of mTNF regulates reverse signaling

[0050] Reference Figure 2 Human embryonic kidney (HEK) cells were transiently transfected for 24 hours and stained with TNF antibody adalimumab (Humira TM ) for 5 minutes. mTNF reverse signaling is indicated by ERK1 / 2 phosphorylation, assessed by western blot. mTNF reverse signaling is not stimulated unless HEK cells express a tumor necrosis factor (TNF) plasmid construct (NT = not transfected); truncation of the intracellular domain of TNF (amino acids 2-25) abolishes reverse signaling (Trunc TNF). Importantly, the cytoplasmic tail of mTNF contains a casein kinase 1 (CK1) recognition site (S(P)-XXS) that is removed in Trunc TNF, indicating the necessity for CK1 binding in mTNF reverse signaling.

[0051] Figure 2 * indicates P < 0.05 by unpaired Student t-test, n = 6-12 biological replicates.

[0052] Example 3: Casein kinase 1 regulates mTNF-mediated myogenic responsiveness

[0053] Reference Figure 3 , the resistance artery of the cremaster skeletal muscle of mice was isolated and cannulated for pressure electromyography. A stepwise increase in transmural pressure (20-100 mmHg in steps of 20 mmHg) induced myogenic vasoconstriction. Figure 3 a) The pan-casein kinase 1 (CK1) inhibitor CKI-7 (10 mM in vitro) reduced myogenic responsiveness. Figure 3 b) CKI-7 does not impair vascular health, as phenylephrine-induced vasoconstriction remains intact. Figure 3 c) CKI-7 caused a dose-dependent decrease in myogenic responsiveness (n=4-6 vessels). Figure 3 d) CKI-7 is ineffective in the absence of TNF signaling (i.e., TNF knockout arteries, TNF KO). Figure 3 e) CKI-7 does not affect phenylephrine-induced vasoconstriction in TNF KO arteries. Figure 3f) Acute administration of mTNF-stimulated fusion protein sTNFR1-Fc (100 ng / mL) stimulated vasoconstriction that was blocked by CKI-7, indicating that mTNF reverse signaling requires functional CK1. Figure 3 g) All vessels were healthy prior to the experiment, showing robust vasoconstriction in response to phenylephrine (PE). (h) Pressure electromyography was performed on isolated cremaster resistance arteries followed by Western blotting for ERK1 / 2 phosphorylation, a molecular readout of mTNF reverse signaling. sTNFR1-Fc stimulates an increase in ERK1 / 2 that is inhibited by CKI-7. (i) Representative Western blots. (j) Mesenteric vascular smooth muscle cells show robust ERK1 / 2 phosphorylation in response to sTNFRI-Fc, which is inhibited by CKI-7 (1 mM).

[0054] ( Figure 3 a,b,d,e) Figure 3 * in a, b, c, d, and e indicates P < 0.05 by unpaired Student t test. ( Figure 3 c, fg) Figure 3 * in c, f and g indicates P < 0.05 by one-way ANOVA and comparison with untreated control responsiveness by Dunnett's post hoc test. * indicates P < 0.05 by one-way ANOVA and comparison with control (Con), and + indicates P < 0.05 by Bonferroni's post hoc test compared with TNFR1-Fc alone (0 mol / L CKI-7). The number of biological replicates is Figure 3 Indicated in brackets.

[0055] Example 4: Casein kinase 1δ regulates myogenic responsiveness

[0056] Reference Figure 4 , the resistance artery of the cremaster skeletal muscle of mice was isolated and cannulated for pressure electromyography. A stepwise increase in transmural pressure (20-100 mmHg in steps of 20 mmHg) induced myogenic vasoconstriction. Figure 4 a) The selective CK1 E inhibitor PF-4800567 abolished myogenic responsiveness (30 mM in vitro). Figure 4 b) PF-4800567 caused a dose-dependent decrease in myogenic responsiveness (n=4-5 per dose), despite concentrations well above the IC 50 (32 nM), suggesting that this decrease in tension may be due to off-target effects of the inhibitor. Figure 4 c) Phenylephrine-induced vasoconstriction is reduced in arteries treated with PF-4800567. Figure 4d) The reduction in phenylephrine-induced vasoconstriction persisted after correction relative to baseline concentration, indicating that PF-4800567 has a nonspecific inhibitory effect at the 30 mM dose. Together, these data suggest that CK1 E is unlikely to mediate myogenic responsiveness, as PF-4800567 was only inhibited at concentrations of PF-4800567 greater than the IC 50 Inhibition of responsiveness to 1000x occurred, while PF-4800567 inhibited general vasoconstriction (as indicated by blunted responsiveness to phenylephrine). Figure 4 e) The CK1 D / E inhibitor PF-670462 reduced myogenic responsiveness (550 nM in vitro), an effect that could be reversed by repeated changes of the vascular incubation buffer. Figure 4 f) PF-670462 is close to the published IC 50 The presence of PF-670462 at concentrations of CK1D (7.7-14 nM) caused a dose-dependent reduction in myogenic responsiveness, suggesting that the reduction in tension may be specific to CK1D or CK1E (n=4-5 at each dose). Since the CK1E-selective inhibitor PF-4800567 is only effective at concentrations well beyond the specific range of CK1E, we believe that the stronger inhibitory effect of PF-670462 is due to targeting CK1D. Figure 4 g) Since PF-670462 inhibits myogenic responsiveness in wild-type (WT) arteries but not in arteries from TNF knockout (TNF - / - ) mice, thus CK1 D signals through TNF. Figure 4 h) PF-670462 does not impair vascular health, as phenylephrine-induced vasoconstriction is intact.

[0057] ( Figure 4 a,c,d) Figure 4 * in a, c, and d indicates P < 0.05 by unpaired Student t test. ( Figure 4 b, f) Figure 4 * in b and f indicates P < 0.05 by one-way ANOVA and compared with the 0 dose by Dunnett's post hoc test. ( Figure 4 e) Figure 4 * in e indicates P < 0.05 by one-way ANOVA and compared with PF-670462 by Dunnett's post hoc test. ( Figure 4 g, h) Figure 4 * in g and h indicates P < 0.05 by one-way ANOVA and compared with the response of WT PF-670462 by Dunnett’s post hoc test. The number of biological replicates is Figure 4 Indicated in brackets.

[0058] Example 5: CK1D regulates circadian oscillations in myogenic responsiveness.

[0059] Reference Figure 5 , mouse cremaster skeletal muscle resistance arteries were isolated at mid-rest (ZT7) or mid-activity (ZT19) and cannulated for pressure electromyography. A one-step increase in transmural pressure (60 to 100 mmHg) induced myogenic vasoconstriction. Figure 5 a) PF-670462 (10 mM, in vitro) reduces myogenic responsiveness only during the resting period (ZT7) but not during the active period (ZT19). Figure 5 b) PF-670462 treatment did not affect vascular dilation, indicating that the initial vascular tension before pressure stimulation was consistent. Figure 5 c) Pressure electromyography was performed on the resistance artery of the cremaster muscle, and ERK1 / 2 phosphorylation was assessed by western blotting. PF-670462 reduced ERK1 / 2 phosphorylation to a greater extent during the resting period (ZT7). Figure 5 d) Representative Western blot. Figure 5 e) The resting diameter of the vessels was not affected by PF-670462. Figure 5 f) Prior to administration of PF-670462, vascular health was intact as shown by robust vasoconstriction in response to phenylephrine. Figure 5 g) PF-670462 dose-dependently reduced myogenic tension at mid-rest (ZT7), reaching a nadir reached at mid-activity (ZT19) (n=4-7 vessels per dose). Figure 5 h) Vascular health, as indicated by potent phenylephrine-induced vasoconstriction, was not affected by PF-670462.

[0060] ( Figure 5 a to d) Figure 5 * in a, b, c, and d indicates that the data were within the same time period (ZT7 or ZT19, respectively), and P < 0.05 by unpaired Student t test. ( Figure 5 e,f) Figure 5 * in e and f indicates P < 0.05 by one-way ANOVA. Figure 5 g) Figure 5 * in g indicates P < 0.05 by one-way ANOVA and compared with the no drug condition (0 pmol / L) in the same time period (ZT7 or ZT 19, respectively) by Dunnett's post hoc test. Figure 5 h) * in 5h indicates P < 0.05 by unpaired Student t test. The number of biological replicates is Figure 5 Indicated in brackets.

[0061] Example 6: CK1D inhibition improves microvascular dysfunction and cardiac performance in HF

[0062] refer to Figure 6 a to 6c, mice underwent myocardial infarction (ligation of the left anterior descending coronary artery) or sham surgery. Eight weeks after myocardial infarction, mice developed heart failure (HF). Cremaster skeletal resistance arteries were isolated and cannulated for pressure electromyography. A stepwise increase in transmural pressure (increased in steps of 20 mmHg, 20-100 mmHg) induced myogenic vasoconstriction, which was significantly greater in the HF group than in the sham group. ( Figure 6 a) Bath treatment with PF-670462 (550 nM in vitro) normalized myogenic responsiveness in arteries from HF mice (i.e., myogenic responsiveness levels were similar to sham values). Figure 6 b) PF-670462 did not affect myogenic tone in sham-operated mice. Figure 6 c) The vessels showed robust function as phenylephrine-induced vasoconstriction was intact.

[0063] Reference Figure 6 d to f, Neonatal mice were treated with PF-670462 (30-50 mg / kg dissolved in 200 μl water, injected intraperitoneally) or vehicle (200 ml water). 24 hours later, pressure electromyography was performed on the resistance artery of the cremaster skeletal muscle at mid-rest (ZT7). Figure 6 d) Both 30mg / kg and 50mg / kg of PF-670462 reduced myogenic responsiveness, indicating that the drug is functional in vivo. Figure 6 e) In vivo application of PF-670462 did not alter phenylephrine-induced vasoconstriction. Figure 6 f) In accordance with the reduction of myogenic tone, acute injection of PF-670462 (30 mg / kg intraperitoneally) reduced mean arterial blood pressure (MAP) (n=3 per group).

[0064] Reference Figure 6 g to j, Mice were chronically treated with PF-670462 (30 mg / kg, ip) or vehicle (DMSO) for 7 weeks (5 days / week) after myocardial infarction or sham surgery. Cremaster skeletal muscle resistance arteries were isolated for pressure electromyography ( Figure 6 g), mRNA expression of CK1D and CK1E in cremaster resistance arteries was not different between HF and sham (n = 18 samples per group), suggesting that differences in myogenic tone are driven by post-translational mechanisms. Figure 6h) HF-induced increases in myogenic tone can be normalized by long-term treatment with PF-670462. Figure 6 i) Phenylephrine-induced vasoconstriction was intact during chronic PF-670462 treatment. The decrease in tone at lower concentrations of phenylephrine in the PF-670462-treated group was a result of changes in resting myogenic tone. Figure 6 j) Long-term PF-670462 treatment improves cardiac output, measured by echocardiography to assess the quantitative flow of blood out of the heart.

[0065] ( Figure 6 a, b and g to j) in Figure 6 In a, b, and g to j, * indicates P < 0.05 by unpaired Student t test. ( Figure 6 c to e) Figure 6 * in c to e indicates P < 0.05 by one-way ANOVA and compared with the control by Dunnett’s post hoc test. The number of biological replicates is Figure 6 Indicated in brackets.

[0066] The present invention shows that CK1 acts as a modulator of mTNF reverse signaling and is therefore a modulator of myogenic responsiveness. The demonstrated ability of CK1 inhibitors to reduce myogenic responsiveness without affecting agonist-induced vasoconstriction provides a substantial safety margin for clinical applications in diseases where microvascular tone is increased.

[0067] References

[0068] 1.Bayliss.On the local reactions of the arterial wall to changes ofinternal pressure.J Physiol.1902;28:220-231.

[0069] 2.Hill et al.Invited review:arteriolar smooth musclemechanotransduction:Ca(2+)signaling pathways underlying myogenic reactivity.JAppl Physiol(1985).2001;91:973-983.

[0070] 3.Schubert et al.The emerging role of Ca2+ sensitivity regulation inpromoting myogenic vasoconstriction.Cardiovasc Res.2008;77:8-18.

[0071] 4.Cole et al.Role of myosin light chain kinase and myosin light chainphosphatase in the resistance arterial myogenic response to intravascularpressure.Arch Biochem Biophys.2011;510:160-173.

[0072] 5.Lidington et al.Capitalizing on diversity:an integrative approachtowards the multiplicity of cellular mechanisms underlying myogenicresponsiveness.Cardiovasc Res.2013;97:404-412.

[0073] 6.Kuo et al.Coronary arteriolar myogenic response is independent ofendothelium.Circ Res.1990;66:860-866.

[0074] 7.Falcone et al.Endothelial independence of myogenic response inisolated skeletal muscle arterioles.Am J Physiol.1991;260:H130-H135.

[0075] 8.Meininger et al.Cellular mechanisms involved in the vascularmyogenic response.Am J Physiol.1992;263:H647-H659.

[0076] 9.Metting et al.Systemic vascular autoregulation amplifies pressorresponses to vasoconstrictor agents.Am J Physiol.1989;256:R98-105.

[0077] 10.Metting et al.Quantitative contribution of systemic vascularautoregulation in acute hypertension in conscious dogs.J Clin Invest.1989;84:1900-1905.

[0078] 11.Petersen et al.Coronary artery myogenic response in a geneticmodel of hypertrophic cardiomyopathy.Am J Physiol Heart Circ Physiol.2002;283:H2244-H2249.

[0079] 12.Hoefer et al.Sphingosine-1-phosphate-dependent activation of p38MAPK maintains elevated peripheral resistance in heart failure throughincreased myogenic vasoconstriction.Circ Res.2010;107:923-933.

[0080] 13.Gschwend et al.Myogenic constriction is increased in mesentericresistance arteries from rats with chronic heart failure:instantaneouscounteraction by acute AT1 receptor blockade.Br J Pharmacol.2003;139:1317.

[0081] 14.Sauvéet al.Tumor Necrosis Factor / Sphingosine-1-Phosphate SignalingAugments Resistance Artery Myogenic Tone in Diabetes.Diabetes.2016;65:1916-1928.

[0082] 15.Ungvari et al.Increased myogenic tone in skeletal musclearterioles of diabetic rats.Possible role of increased activity of smoothmuscle Ca2+ channels and protein kinase C.Cardiovasc Res.1999;43:1018-1028.

[0083] 16.Matrougui et al.High sodium intake decreases pressure-induced(myogenic)tone and flow-induced dilation in resistance arteries fromhypertensive rats.Hypertension.1998;32:176-179.

[0084] 17.Rowell.Human cardiovascular adjustments to exercise and thermalstress.Physiol Rev.1974;54:75-159.

[0085] 18.Kroetsch et al.Constitutive smooth muscle tumour necrosis factorregulates microvascular myogenic responsiveness and systemic bloodpressure.Nat Commun.2017;8:14805.

[0086] 19.Watts et al.A casein kinase I motif present in the cytoplasmicdomain of members of the tumour necrosis factor ligand family is implicatedin reverse signalling.EMBO J.1999;18:2119-2126.

[0087] 20.Venerando et al.Casein kinase:the triple meaning of amisnomer.Biochem J.2014;460:141-156.

[0088] 21.Gross et al.Casein kinase I:spatial organization and positioningof a multifunctional protein kinase family.Cell Signal.1998;10:699-711.

[0089] 22.Knippschild et al.The casein kinase 1 family:participation inmultiple cellular processes in eukaryotes.Cell Signal.2005;17:675-689.

[0090] 23.Cheong et al.Casein kinase 1:Complexity in the family.Int JBiochem Cell Biol.2011;43:465-469.

[0091] 24.Pulgar et al.Optimal sequences for non-phosphate-directedphosphorylation by protein kinase CK1(casein kinase-1)--a re-evaluation.Eur JBiochem.1999;260:520-526.

[0092] 25.Roach.Multisite and hierarchal protein phosphorylation.J BiolChem.1991;266:14139-14142.

Claims

1. Use of PF-670462 in the manufacture of a medicament for preventing and / or treating heart failure.

2. The use according to claim 1, wherein: The PF-670462 is administered to the patient once, twice or three times daily.

3. The use according to claim 2, wherein: The PF-670462 is administered to the subject according to a regimen that provides a maximal pharmacological effect of PF-670462 during the subject's resting state.

4. The use according to claim 3, wherein: The PF-670462 is administered to the subject according to a regimen that provides the maximal pharmacological effect of PF-670462 during mid-rest phase, or between -2 hours and +2 hours during mid-rest phase.

5. The use according to claim 4, wherein: PF-670462 is administered to subjects according to a regimen that provides maximal pharmacological effect of PF-670462 between -1 hour and +1 hour during mid-rest.

Citation Information

Patent Citations

  • Casein kinase 1 inhibitors for the treatment of b-cell chronic lymphocytic|leukemia

    WO2014023271A1

  • Casein kinase 1 inhibitors for the treatment of b-cell chronic lymphocytic|leukemia

    US20150209354A1

  • Treatment of TNF-alpha-mediated disorders with casein kinase i epsilon inhibitors

    WO2004035076A1